Skip to main content

UPDATE: Compugen Signs Novartis to Multimillion Dollar LEADS License

NEW YORK, Aug. 2 – Compugen has licensed its LEADS computational biology platform to Novartis, the company announced on Thursday.

The deal, which will run for one year with the option for Novartis to extend two additional years, also includes a proprietary DNA chip design to represent Novartis’ transcriptome database. The deal is worth a "few million dollars" Compugen CEO Mor Amitai told GenomeWeb.

"For us this is a big deal," said Amitai. "Financially, it is substantial, and it [also] means working with one of the best functional genomics groups in the world. It is an imporant validation for us and our technologies." Amitai added that the agreement would allow Compugen to improve its tools based on Novartis' feedback.

The LEADS bioinformatics platform incorporates genomics and proteomics tools and public and proprietary databases. Other licensees include Human Genome Sciences and Pfizer.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.